Question explored with the scientific record
How is the pneumonia vaccine for people about 72 years old but relatively good health
The short version: for a healthy 72-year-old, the pneumonia vaccine is a modest bet, not a slam dunk. It cuts one specific kind of pneumonia, not pneumonia in general, and the best evidence is in people sicker than you.
The strongest data come from a large randomized trial in adults 65 and older, the kind of trial that can actually prove cause and effect. It found the conjugate vaccine (PCV13) cut vaccine-type pneumonia by about 46% and invasive pneumococcal disease by about 75% [2]. But it did not significantly reduce pneumonia from all causes [2][4]. So the benefit is real but narrow: it protects against the strains in the shot, not the many other bugs that cause pneumonia.
| Outcome | What the trial showed |
|---|---|
| Vaccine-type pneumonia | ~46% fewer cases [2] |
| Invasive pneumococcal disease | ~75% fewer cases [2] |
| Pneumonia from any cause | No significant reduction [2][4] |
| All-cause death (older polysaccharide shot) | No significant reduction [3] |
The older polysaccharide vaccine (PPSV23) is weaker. A 2024 meta-analysis found it did not significantly reduce all-cause death, though it did cut pneumonia-related death [3]. One observational study found no clear benefit in people without HIV [1]. And immune response does blunt with age, so a 72-year-old mounts a weaker response than a 50-year-old [5][6].
On safety, the trials reported more local reactions but no serious vaccine-related events [2][4]. That is short-term data. This retrieval contains no long-term safety study, and absence of evidence is not evidence of safety.
My call: a reasonable, low-risk choice for a healthy 72-year-old, with a modest and narrow benefit, not a must. Confidence: moderate.
Sources used 6
-
Impact of Pneumococcal Vaccination on the Incidence of Pneumonia by HIV Infection Status among Patients Enrolled in the Veterans Aging Cohort 5‐Site Study
A prospective Veterans Affairs cohort study shows that pneumococcal vaccination (PPV) reduces pneumonia risk among HIV-infected veterans, while showing no clear benefit in HIV-uninfected veterans, after adjusting for multiple comorbidities and HIV-related factors.
DOI: 10.1086/529201 -
Is 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Combined With 23-Valent Pneumococcal Polysaccharide Vaccine (PPSV23) Superior to PPSV23 Alone for Reducing Incidence or Severity of Pneumonia in Older Adults? A Clin-IQ
PCV13 reduced vaccine-type pneumococcal CAP and invasive pneumococcal disease in older adults and had no serious adverse events, but did not significantly reduce all-cause CAP or non-vaccine-type CAP; the review concludes PCV13 is effective for vaccine-type disease.
DOI: 10.17294/2330-0698.1214 -
Mortality reduction with 23-valent pneumococcal polysaccharide vaccine: a systematic review and meta-analysis
This systematic review and meta-analysis evaluated the effectiveness of the 23-valent pneumococcal polysaccharide vaccine (PPV23) in reducing all-cause and pneumonia-related mortality among adults, finding no significant reduction in all-cause mortality but a significant reducti…
DOI: 10.1186/s41479-024-00149-5 -
How effective is 13-valent pneumococcal conjugate vaccine (PCV13) combined with 23-valent pneumococcal polysaccharide vaccine (PPSV23)?
This systematic review of 10 studies concluded that PCV13 combined with PPSV23 produces a greater immune response than PPSV23 alone in adults aged 50 years and older, with no vaccine-related serious adverse events reported, but clinical superiority remains unresolved.
DOI: 10.33178/smj.2021.1.3 -
B Cell Immunosenescence
A comprehensive review of how aging affects B cell development, subsets, antibody production, and vaccine responses, highlighting inflammaging, obesity as a modulator, CMV and microbiome influences, and the emergence of proinflammatory B cell types that diminish humoral immunity…
DOI: 10.1146/annurev-cellbio-011620-034148 -
Regulatory T cells and vaccine effectiveness in older adults. Challenges and prospects
This minireview synthesizes current knowledge on how regulatory T cells (Tregs) influence vaccine responses in older adults, highlighting aging-associated Treg expansion as a factor in reduced vaccine effectiveness and outlining strategies to modulate Tregs to improve immunogeni…
DOI: 10.1016/j.intimp.2021.107761